DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
Journal of Korean Medical Science
; : 207-213, 2011.
Artigo
em Inglês
| WPRIM (Pacífico Ocidental)
| ID: wpr-123289
Biblioteca responsável:
WPRO
ABSTRACT
DNA methyltransferase inhibitor, 5-azacitidine (AC) is effective in myelodysplastic syndromes (MDS) and can induce re-expression in cancer. We analyzed the methylation of 25 tumor suppressor genes in AC-treated MDS. Hypermethylation of CDKN2B, FHIT, ESR1, and IGSF4 gene was detected in 9/44 patients. In concordance with the clinical response, a lack of or decreased methylation in 4 patients with hematologic improvements and persistent methylation in 4 others with no response was observed. The mRNA expression of CDKN2B, IGSF4, and ESR1 was significantly reduced in MDS. Our results suggest that methylation changes contribute to disease pathogenesis and may serve as marker to monitor the efficacy of treatments.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Azacitidina
/
Síndromes Mielodisplásicas
/
Metilases de Modificação do DNA
/
Genes Supressores de Tumor
/
Metilação de DNA
/
Inibidores Enzimáticos
Limite:
Adolescente
/
Adulto
/
Idoso
/
Idoso, 80 anos ou mais
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Journal of Korean Medical Science
Ano de publicação:
2011
Tipo de documento:
Artigo